Advertisement

Medical Oncology

, Volume 28, Issue 2, pp 608–614 | Cite as

β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells

  • Xiangrong Liu
  • Lei Wang
  • Shangfeng Zhao
  • Xunming Ji
  • Yumin Luo
  • Feng Ling
Original Paper

Abstract

β-Catenin, a core component of Wnt/β-catenin signaling, has been shown to be a crucial factor in a broad range of tumors, while its role in glioma is not well understood. In this study, the expression of β-catenin in astrocytic glioma tissues with different grade and human normal cerebral tissues was examined using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. We found a higher expression level of β-catenin in astrocytic glioma patients with high grade in comparison with the normal controls. Additionally, siRNA was transfected into human U251 glioblastoma cells by liposome after the design of siRNA was confirmed to effectively inhibit the expression of β-catenin by RT-PCR. Compared to the control siRNA group, siRNA-mediated knockdown of β-catenin in human U251 cells inhibited cell proliferation, resulted in cell apoptosis, and arrested cell cycle in G 0/G 1. Additionally, downregulation of β-catenin decreased the expression level of cyclin D1, c-Myc and c-jun. Taken together, these results indicate that overexpression of β-catenin may be an important contributing factor to glioma progression.

Keywords

Apoptosis β-catenin Glioma Growth inhibition RNA interference 

Notes

Acknowledgments

We are grateful to Prof. Qing Rao and Prof. Min Wang (Institute of Hematology and Blood Disease Hospital, China) for technical support. This work was supported by Postdoctoral Science Found (20080440423) of China and Clinical and Basic Cooperation Fund of Capital University of Medical Sciences (2006JL36).

References

  1. 1.
    Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science. 2000;287:1606–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837–51.PubMedGoogle Scholar
  4. 4.
    Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol. 2008;468:5–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene. 2005;24:2410–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Gavert N, Ben-Ze’ev A. Beta-catenin signaling in biological control and cancer. J Cell Biochem. 2007;102:820–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Dihlmann S, von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 2005;113:515–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology. 2004;36:120–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Hatsell S, Rowlands T, Hiremath M, Cowin P. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2003;8:145–58.PubMedCrossRefGoogle Scholar
  10. 10.
    Mann B, et al. Target genes of β-catenin-T cell-factor/lymphoidenhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA. 1999;96:1603–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Rowlands TM, Pechenkina IV, Hatsell S, Cowin P. Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle. 2004;3:145–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Pu P, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009;16:351–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP. Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int. 2009;55:307–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Liu X, et al. Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia. 2009;23:739–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using a small interference RNAs. Methods. 2002;26:199–213.PubMedCrossRefGoogle Scholar
  16. 16.
    Müller T, Choidas A, Reichmann E, Ullrich A. Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem. 1999;274:10173–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Utsuki S, et al. Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol. 2002;57:187–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Sareddy GR, Challa S, Panigrahi M, Babu PP. Wnt/beta-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem Res. 2009;34:1278–88.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Dang CV, et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Saadeddin A, Babaei-Jadidi R, Spencer-Dene B, Nateri AS. The links between transcription, beta-catenin/JNK signaling, and carcinogenesis. Mol Cancer Res. 2009;7:1189–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Takayama S, Rogatsky I, Schwarcz LE, Darimont BD. The glucocorticoid receptor represses cyclin D1 by targeting the TCF/beta-catenin complex. J Biol Chem. 2006;281:17856–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Xiangrong Liu
    • 1
  • Lei Wang
    • 2
  • Shangfeng Zhao
    • 3
  • Xunming Ji
    • 1
  • Yumin Luo
    • 1
  • Feng Ling
    • 1
  1. 1.Cerebrovascular Diseases Research Institute, Key Laboratory of Neurodegenerative Diseases of Ministry of Education and Department of Neurosurgery, Xuanwu HospitalCapital Medical UniversityBeijingPeople’s Republic of China
  2. 2.Department of Neurosurgery, Beijing Tiantan HospitalCapital University of Medical SciencesBeijingPeople’s Republic of China
  3. 3.Department of Neurosurgery, Beijing Tongren HospitalCapital University of Medical SciencesBeijingPeople’s Republic of China

Personalised recommendations